MGI Tech's Berlin Hub Celebrates 2nd Anniversary, Intensifying European Expansion

MGI Tech Co., Ltd. (688114.SH) has established its Customer Experience Center (CEC) in the Adlershof science and technology park in Berlin, Germany. The CEC is now a key base for MGI Tech's expansion into the European bio market. The 2nd anniversary marks more than just the establishment of a branch; it is part of MGI's broader European and global expansion strategy, which gained momentum after the $325 million patent dispute settlement with Illumina (ILMN). The CEC enables MGI to build a local ecosystem where its DNBSEQ platform can be directly validated and optimized, maximizing its technological credibility in the NGS (Next Generation Sequencing) market.

Reducing Barriers to Technology Adoption and Supporting Customized R&D Infrastructure

European biotech startups and academic research institutions have faced significant barriers when adopting high-end NGS platforms, including substantial upfront investment costs and technical uncertainties. The Berlin CEC provides an 'Open Lab' where they can test multi-omics workflows, such as DNA-omics, cell-omics, spatial-omics, and proteomics, using real samples. This practical infrastructure reduces the trial-and-error associated with adopting new technologies and shortens the adoption cycle, fostering a 'lock-in' effect for MGI's platform within the local ecosystem.

The Impact of Platform Diversification and an Open Ecosystem

The Berlin CEC features a Demo Lab and an Alpha Lab, where MGI's flagship equipment, including the DNBSEQ-G400 and DNBSEQ-T7 high-throughput sequencing platforms, can be directly operated and demonstrated. MGI promotes an open platform architecture that is compatible with third-party reagents and analysis software, actively supporting customized analysis development. This emphasis on compatibility differentiates MGI from established market leaders who maintain closed ecosystems, enabling flexible research designs and improving genomic analysis efficiency.

Intensifying Competition in the Global Diagnostics and Precision Medicine Market

The global NGS market is estimated at $13.3 billion to $18 billion by 2026 and is growing rapidly at over 15% annually, driven by increasing demand for precision medicine and early cancer diagnostics. In this competitive landscape, where Illumina, Pacific Biosciences, and Oxford Nanopore are vying for market share, MGI aims to expand its market share by leveraging the high accuracy and cost-effectiveness of its proprietary DNB (DNA Nanoball) technology. The local support provided through the CEC goes beyond simple equipment sales and is expected to accelerate the entry of CE-IVDR-certified platforms into the clinical and diagnostics sectors in the highly regulated European market.

Synergy between Clinical and Diagnostic Markets and Digital Healthcare

Ultimately, MGI's strengthened Berlin CEC is aligned with the shift towards a digital healthcare paradigm that integrates genomic data into clinical decision-making in real-time. Clinical and commercial diagnostic labs need to perform large-scale tests accurately and quickly, making the integration of automated systems and data pipelines essential. The automated workflows and real-time data analysis validation provided by the CEC proactively control operational risks and contribute to the advancement of precision medicine infrastructure across Europe.